|
|
Article: Dynavax's Ragweed Allergy Therapy, TOLAMBA(TM), Achieves Primary Efficacy and Safety Endpoints in Phase 2/3 Trial.
- Article from:
- PR Newswire
- Article date:
- January 18, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Statistical Significance Achieved in Primary Endpoint (p=0.024) and Major Secondary Endpoints; Pivotal Phase 3 Trial Anticipated to Begin First Half of 2006
BERKELEY, Calif., Jan. 18 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation announced that results from a two-year Phase 2/3 clinical trial of TOLAMBA, a ragweed allergy immunotherapeutic, showed that patients treated with TOLAMBA experienced a statistically significant reduction in total nasal symptom scores (TNSS) compared to placebo-treated patients in the second year of the trial, the primary efficacy endpoint of the study (p=0.024). Results also showed significant clinical benefit relative to ...